2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur |
|
|
| Not yet recruiting | 2 | 154 | Europe | Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula | Uppsala University Hospital, Roche AB | In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
| Withdrawn | 2 | 22 | NA | Niraparib Tosylate Monohydrate, Zejula | David Liebner, MD | Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IV Retroperitoneal Sarcoma AJCC v8, Unresectable Leiomyosarcoma | 12/24 | 12/25 | | |
NCT05515575: A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA |
|
|
| Active, not recruiting | 2 | 8 | US | Niraparib | Memorial Sloan Kettering Cancer Center, GlaxoSmithKline | Sarcoma,Soft Tissue, Sarcoma Uterus | 08/26 | 08/26 | | |
